U.S. market Closed. Opens in 3 hours 30 minutes

NRSNW | NeuroSense Therapeutics Ltd. Stock Overview

(Stock Exchange: NASDAQ)
Day's Range 0.1650 - 0.1800
52 Week Range 0.1650 - 0.1800
Beta N/A
Implied Volatility N/A
IV Rank N/A
Day's Volume 10,728
Average Volume N/A
Shares Outstanding 139,145,920
Market Cap 25,046,266
Sector Healthcare
Industry Biotechnology
IPO Date N/A
Valuation
Profitability
Growth
Health
P/E Ratio -0.19
Forward P/E Ratio N/A
EPS -0.94
1YR Price Target N/A
Dividend Yield N/A
Dividend Per Share N/A
Dividend ExDate N/A
Dividend PayDate N/A
Employees 18
Country Israel
Website NRSNW
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for debilitating neurodegenerative diseases in Israel. Its lead product candidate is PrimeC, a novel oral formulation for the treatment of amyotrophic lateral sclerosis. The company's preclinical pipeline product candidates include StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel.
NRSNW's peers: NRSN, KTTAW, GOVXW, NLSPW, CINGW, NXGLW
*Chart delayed
Analyzing fundamentals for NRSNW we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is frighteningly weak. For more detailed analysis please see NRSNW Fundamentals page.

Watching at NRSNW technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, as well as bullish short-term trend. More technicals details can be found on NRSNW Technicals page.
An error has occurred. This application may no longer respond until reloaded. Reload 🗙